NIH nearing the end of peer review review

NIH will hold a final working group meeting tomorrow (October 25) to discuss how to linkurl:amend peer review.;http://enhancing-peer-review.nih.gov/index.html The agency linkurl:kicked off;http://www.the-scientist.com/blog/display/53276/ its review of peer review this summer with the aim of "optimizing its efficiency and effectiveness" - a process many researchers have agreed is needed. The plan is to present results of the series of meetings at the end of this year, and to propose recommendatio

Written byAlla Katsnelson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
NIH will hold a final working group meeting tomorrow (October 25) to discuss how to linkurl:amend peer review.;http://enhancing-peer-review.nih.gov/index.html The agency linkurl:kicked off;http://www.the-scientist.com/blog/display/53276/ its review of peer review this summer with the aim of "optimizing its efficiency and effectiveness" - a process many researchers have agreed is needed. The plan is to present results of the series of meetings at the end of this year, and to propose recommendations for change in January. linkurl:David Kaplan,;http://path-www.path.cwru.edu/information6.php?info_id=30 a researcher at Case Western who has been very outspoken about peer review issues (he linkurl:wrote;http://www.the-scientist.com/article/display/15501/ two linkurl:opinions;http://www.the-scientist.com/article/display/15701/ for The Scientist on what's wrong with the current system) told me yesterday that he doesn't have much hope that any real change will come out of this review process. "Periodically, they review the process and find, 'Gee, we're not doing so well in identifying innovative stuff,'" he said. But the committee reviewing the process consists of prominent researchers such as Keith Yamamoto and Bruce Alberts from UCSF and Alan Leshner of AAAS - scientists who have excelled in the current system and thus are unlikely to see problems with it. "This is not a committee that's going to do that," he said. This limitation is similarly evident in peer review itself, stacking the deck against innovation, he said: "The choice [about which grants get funded] are being made by a very few people" - again, those that are most established. He thinks that more reviewers should assess applications, and that this group should include reviewers outside that sphere, such as postdocs, assistant professors, or researchers with fewer publications. Even efforts like the one announced this summer, to fund linkurl:"wild and crazy";http://www.the-scientist.com/blog/display/53456/ projects fall short, he said. "The irony is, these are people they would have funded anyway." Kaplan is quick to note that he doesn't believe that the current system should be thrown away, but widening the body of reviewers is just part of the fix that's needed. Some of his past suggestions have included cutting grant proposals down to a page or two, and getting rid of the false precision of the 41-point scale used to assess proposals. He has also linkurl:suggested;http://www.the-scientist.com/pubmed/17267383 a statistical measure for judging innovation, which could be built into the review process, and an overhall of statistical techniques the NIH uses in grant review, a proposal he presented to the Peer Review Advisory Committee last year.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies